slno,preds
0,"Here are the reasoning steps:

1. The patient has two distinct adenocarcinomas in the lung, both with free margins and no lymph node metastasis, which suggests that the cancer is localized and has not spread to other parts of the body.

2. The molecular studies revealed a positive KRAS mutation, which is associated with poor prognosis. This suggests that the patient's cancer may be more aggressive and have a worse outcome.

3. However, the patient's cancer is localized and has not spread to other parts of the body, which is a good prognostic factor.

4. Considering the patient's cancer is localized and has a poor prognosis due to the KRAS mutation, it is likely that the patient will not survive for 2.48 years.

Answer - {""Survival"": ""False""}"
1,"Here are the reasoning steps:

1. The patient has a diagnosis of lung cancer, specifically a moderately differentiated adenocarcinoma.
2. The tumor is staged as T2N0, indicating that it is 2 cm in size and has not spread to the lymph nodes.
3. There is focal pleural invasion, but no lymphovascular space invasion.
4. All biopsied lymph nodes were negative for neoplasm, with some showing anthracotic pigment and reactive changes.

Based on these findings, the patient's prognosis is generally good. The tumor is localized and has not spread to the lymph nodes, which is a favorable indicator. The presence of focal pleural invasion is a negative factor, but it is not a major concern in this case.

Therefore, the answer is:

{""Survival"": ""True""}"
2,"Here are the reasoning steps:

1. The patient underwent a left lower lobectomy, which suggests that the tumor was localized to the left lower lobe and was removed surgically.
2. The tumor is well-differentiated, minimally invasive, and has negative surgical margins, which indicates that the tumor is likely to be a low-grade, early-stage cancer.
3. There is no evidence of lymphovascular invasion or visceral pleura invasion, which suggests that the tumor has not spread to the lymph nodes or the pleura.
4. The lymph node examinations from various sites showed no malignancy in the sampled nodes, which confirms that the cancer has not spread to the lymph nodes.
5. The staging is pT1b, pN1, which indicates that the tumor is stage 1B, with no evidence of lymph node metastasis.

Based on these findings, it is likely that the patient will survive for at least 2.48 years after surgery."
3,"Here are the reasoning steps:

1. The patient has a diagnosis of moderately-poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor size is relatively small, measuring 2.5 x 2.0 cm, which is a favorable factor.
3. However, the tumor has extensive lymphovascular invasion, which is a poor prognostic factor.
4. The most concerning finding is that 10 out of 12 lymph nodes are involved with metastatic carcinoma, including the subcarinal lymph node, which is a common site for lymph node metastasis.
5. The two lymph nodes that are free of tumor are not enough to overcome the significant lymph node involvement.
6. The surgical margins are negative for tumor, which is a favorable factor.
7. Considering the aggressive nature of the tumor, the extensive lymphovascular invasion, and the significant lymph node involvement, it is likely that the patient will not survive for 2.48 years.

Answer: {""Survival"": ""False""}"
4,"Here are the reasoning steps:

1. The patient has a diagnosis of invasive poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor is 2.7 cm in size, which is relatively large, and has invaded the visceral pleura, which is a poor prognostic factor.
3. The tumor also has intratumoral large vessel invasion, which is a sign of aggressive behavior.
4. The patient has a parenchymal margin of 8 mm, which is relatively small, indicating that the tumor is close to the edge of the resected lung tissue.
5. Despite the aggressive features of the tumor, the patient does not have any evidence of distant metastasis.

Based on these factors, I would conclude that the patient's prognosis is poor, and they are unlikely to survive for 2.48 years. Therefore, the answer is:

{""Survival"": ""False""}"
5,"Here are the reasoning steps:

1. The patient has a diagnosis of invasive mucinous adenocarcinoma, which is a type of lung cancer.
2. The tumor is 2.5 cm in size, which is relatively small.
3. The margins are clear, indicating that the tumor has been completely removed.
4. All examined lymph nodes are negative for carcinoma, indicating no regional lymph node metastasis.
5. The molecular studies revealed a positive KRAS mutation, which is a known predictor of poor prognosis and resistance to certain therapies.

Based on these findings, I would conclude that the patient has a relatively good prognosis, but the presence of a KRAS mutation suggests that the patient may have a poorer outcome compared to patients without this mutation.

Answer: {""Survival"": ""False""}"
6,"Here are the reasoning steps:

1. The patient has a diagnosis of invasive grade 3 adenocarcinoma, which is an aggressive type of cancer.
2. The tumor is 5 x 4 x 3 cm in size, which is relatively large.
3. The tumor has metastasized to one of six intrapulmonary peribronchial lymph nodes, indicating that the cancer has spread beyond the primary tumor site.
4. The patient has a pTNM stage of pT2 N1, which indicates that the tumor is 5 cm or larger in size and has spread to one or more lymph nodes.
5. The patient does not have any evidence of visceral pleural or lymphovascular invasion, which is a good prognostic factor.
6. The patient does not have any evidence of distant metastasis, as the lymph nodes from the inferior and superior mediastinum were negative for tumor.

Based on these factors, I would conclude that the patient has a poor prognosis and is unlikely to survive for 2.48 years.

Answer: {""Survival"": ""False""}"
7,"Here are the reasoning steps:

1. The pathology report indicates a diagnosis of moderately differentiated adenocarcinoma, which is a type of non-small cell lung cancer (NSCLC).
2. The tumor size is 2.3 cm, which is relatively small.
3. The tumor does not invade the visceral pleura, which is a good prognostic factor.
4. There is no evidence of metastatic carcinoma in the examined lymph nodes, which suggests that the disease is localized.
5. The final staging is pT1b N0, which indicates that the tumor is limited to the lung and has not spread to the lymph nodes.

Based on these factors, I would conclude that the patient has a good prognosis and is likely to survive after 2.48 years.

Answer: {""Survival"": ""True""}"
8,"Here are the reasoning steps:

1. The patient has invasive moderately differentiated adenocarcinoma, which is a type of lung cancer.
2. The tumor has metastasized to one of four hilar lymph nodes, indicating that the cancer has spread beyond the primary tumor site.
3. However, the surgical margins, including the bronchial resection margin, are negative for carcinoma, indicating that the tumor has been completely removed.
4. There is no evidence of pleural involvement or angiolymphatic invasion, which suggests that the cancer has not spread to other parts of the body.
5. The presence of hyalinized granulomata in additional biopsies from various lymph nodes is not relevant to the patient's survival.

Based on these findings, I conclude that the patient has stage II lung cancer, which has a 5-year survival rate of around 40-50%. However, since the patient has undergone complete resection of the tumor, their 2.48-year survival rate is likely to be higher.

Answer: {""Survival"": ""True""}"
9,"Here are the reasoning steps:

1. The pathology report indicates an invasive well-differentiated adenocarcinoma with a predominant bronchiolo-alveolar carcinoma component, which suggests a relatively slow-growing tumor.
2. The tumor measures approximately 50 x 60 x 45 mm, which is a relatively large size, but the report does not indicate any evidence of vascular or perineural invasion, which are poor prognostic factors.
3. The tumor does not metastasize to hilar lymph nodes, which suggests that the cancer has not spread to distant sites.
4. Although the tumor closely abuts the pleural surface, confirmatory stains suggest that the pleura is likely not involved, which reduces the risk of pleural metastases.
5. The report also mentions a separate specimen from the back that shows features consistent with a lipoma, with no evidence of malignancy, which suggests that the patient does not have any other concurrent malignancies.

Based on these findings, I would conclude that the patient has a relatively good prognosis and is likely to survive after 2.48 years.

Answer: {""Survival"": ""True""}"
10,"Here are the reasoning steps:

1. The patient has a poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor has invaded the visceral pleura, which indicates that it has spread beyond the primary tumor site.
3. The tumor has also metastasized to one of the examined lymph nodes, which suggests that the cancer has spread to other parts of the body.
4. The immunohistochemical staining results are positive for CD15, CK7, TTF1, and CEA, which are markers commonly associated with lung adenocarcinoma.
5. However, the staining results are negative for CK20 and CDX2, which are markers more commonly associated with other types of cancer.

Based on these findings, it is likely that the patient has a more advanced stage of lung cancer, with a higher risk of recurrence and poor prognosis.

Answer: {""Survival"": ""False""}"
11,"Here are the reasoning steps:

1. The patient has a tumor in the left lower lobe of the lung, measuring 4.0 x 3.5 x 2.0 cm, diagnosed as adenocarcinoma of mixed subtype, predominantly papillary.
2. The tumor has infiltrated the visceral pleura, which is a poor prognostic factor.
3. The tumor is classified as pT2, which indicates that it has invaded the lung tissue, but not the chest wall or diaphragm.
4. There is no regional lymph node involvement (0/20), which is a good prognostic factor.
5. The distant metastasis status is unknown (pMx), which means that the patient may or may not have metastases elsewhere in the body.
6. The tumor grade is G2, indicating moderate differentiation, which is a good prognostic factor.

Based on these factors, I would conclude that the patient has a moderate-risk lung cancer, with a potential for distant metastases. However, the lack of regional lymph node involvement and moderate differentiation suggest that the patient may have a better prognosis.

Answer: {""Survival"": ""True""}"
12,"Here are the reasoning steps:

1. The patient underwent a right upper lobe lobectomy, which suggests that the tumor was localized to the right upper lobe and was removed surgically.
2. The tumor is moderately differentiated adenocarcinoma, which is a more favorable histology compared to poorly differentiated or undifferentiated tumors.
3. There is no angiolymphatic invasion, which means that the tumor did not invade blood vessels or lymphatic vessels, which is a good prognostic factor.
4. The tumor did not involve the pleura, which is a good sign as pleural involvement can indicate more advanced disease.
5. The bronchial margin is negative, which means that the tumor did not extend to the bronchial resection margin.
6. Metastatic adenocarcinoma was found in 1 out of 4 peribronchial lymph nodes, which suggests that the tumor has spread to the lymph nodes, but the extent of spread is limited.
7. No metastatic carcinoma was identified in the R4 and station 11 lymph nodes, which suggests that the tumor has not spread to other lymph nodes.

Based on these findings, I would conclude that the patient has a good prognosis and is likely to survive after 2.48 years. Therefore, the answer is:

{""Survival"": ""True""}"
13,"Here are the reasoning steps:

1. The patient has a diagnosis of pulmonary adenocarcinoma, which is a type of non-small cell lung cancer (NSCLC).
2. The tumor size is 1.2 cm, which is relatively small.
3. The tumor is moderately to poorly differentiated, which suggests that it may have a worse prognosis.
4. There is focal invasion into the visceral pleura, which is a sign of local invasion.
5. There is also a focus suggestive of lymphatic invasion, which suggests that the tumor may have spread to the lymphatic system.
6. However, there is no lymph node involvement detected among the seven examined, which suggests that the tumor has not spread to the lymph nodes.
7. The report recommends further mutation analysis for EGFR and KRAS to guide potential targeted therapy options, which suggests that the patient may be a candidate for targeted therapy.

Based on these findings, I would conclude that the patient has a relatively early-stage NSCLC with a moderate to poor prognosis. However, the patient may be a candidate for targeted therapy, which could improve their survival chances.

Answer: {""Survival"": ""True""}"
14,"Here are the reasoning steps:

1. The patient has a diagnosis of adenocarcinoma, acinar type, grade III, which is a poorly differentiated tumor.
2. The tumor is 4 cm in size and invades the visceral pleura, indicating a higher stage tumor.
3. The tumor has metastasized to two of four lymph nodes examined, indicating regional lymph node involvement (N2).
4. The staging is pT2, N2, Mx, which indicates that the tumor is stage IIIB, with metastasis to lymph nodes and no distant metastasis (Mx).

Based on these findings, the patient has a poor prognosis and is unlikely to survive for 2.48 years. The answer is:

{""Survival"": ""False""}"
15,"Here are the reasoning steps:

1. The patient has a large tumor size of 9.2 cm, which is a poor prognostic factor.
2. The tumor has invaded the chest wall, which is a sign of advanced disease.
3. The tumor has a pathological staging of pT3, which is also a poor prognostic factor.
4. There is no evidence of lymph node metastasis, which is a good prognostic factor.
5. The tumor is moderately differentiated, which is a relatively good prognostic factor.

Considering these factors, the patient's prognosis is poor due to the large tumor size, chest wall invasion, and advanced pathological staging. Therefore, the answer is:

{""Survival"": ""False""}"
16,"Here are the reasoning steps:

1. The patient has a diagnosis of lung adenocarcinoma with regional lymph node involvement, which indicates that the cancer has spread to the lymph nodes.
2. The tumor is moderately differentiated, which suggests that it is a more aggressive type of cancer.
3. The tumor measures 6.9 cm, which is a relatively large size, indicating that the cancer has progressed to a more advanced stage.
4. The tumor has visceral pleural invasion, which means that it has invaded the lining of the lung, and lymphangitic invasion, which means that it has invaded the lymphatic vessels.
5. Despite the presence of regional lymph node involvement, there is no evidence of distant metastasis.

Based on these findings, it is likely that the patient will not survive for 2.48 years. The cancer has spread to the lymph nodes and has invaded the surrounding tissues, indicating a more advanced stage of disease.

Answer: {""Survival"": ""False""}"
17,"Reasoning steps:

1. The pathology report does not provide any specific diagnostic information about the case, including the type of tumor, its size, location, or any relevant histological features.
2. The report only mentions that the specimen was sent to the IGC Biospecimen Core Resource (BCR) and provides instructions for completing the TCGA Missing Pathology Report Form.
3. The lack of specific diagnostic information makes it impossible to determine the patient's prognosis or survival rate.

Answer: {""Survival"": ""Insufficient Information""}"
18,"Here are the reasoning steps:

1. The pathology report indicates a diagnosis of well-differentiated papillary non-mucinous adenocarcinoma, which is a relatively slow-growing and less aggressive type of lung cancer.
2. The tumor is classified as stage I B, indicating that it is localized to the lung and has not spread to lymph nodes or distant sites.
3. The resection margins are clear of tumor, denoted as R0, which means that the entire tumor was removed during surgery and there is no evidence of residual cancer.
4. There is no evidence of lymph node involvement (pN0) or distant metastasis (pMX).

Based on these findings, the patient is likely to survive for at least 2.48 years without evidence of recurrence or progression of the disease.

Answer: {""Survival"": ""True""}"
19,"Here are the reasoning steps:

1. The patient has a poorly differentiated adenocarcinoma with visceral pleural and lymphovascular invasion, which indicates an aggressive tumor behavior.
2. The tumor is present at the pleural surface, which suggests that it has already spread to the pleura, a common site for metastasis.
3. One of the six lymph nodes examined contains metastatic carcinoma with extracapsular extension, which indicates that the tumor has already spread to the lymph nodes and has broken through the capsule, allowing it to spread further.
4. The tumor is staged as pT2aN1MX, which indicates that it has spread to the lymph nodes (N1) and has distant metastasis (MX).

Based on these findings, it is likely that the patient will not survive for 2.48 years. The tumor has already spread to the lymph nodes and has distant metastasis, which indicates a poor prognosis.

Answer: {""Survival"": ""False""}"
20,"Here are the reasoning steps:

1. The pathology report describes a poorly differentiated bronchiolo-alveolar adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor size is 2.5 x 1.5 x 3 cm, which is relatively large.
3. There is no information provided about the tumor's extent, other nodules, lymph nodes, or invasion, which makes it difficult to assess the stage and prognosis of the disease.
4. The report does not mention any positive or negative features that would suggest a better or worse prognosis.
5. Given the lack of information about the tumor's extent and stage, it is difficult to predict the patient's survival rate.

Based on these steps, I would select the answer:

{""Survival"": ""False""}

Note: The lack of information about the tumor's extent and stage makes it difficult to predict the patient's survival rate, and the poorly differentiated nature of the tumor suggests a poorer prognosis."
21,"Here are the reasoning steps:

1. The pathology report indicates a diagnosis of moderately-differentiated adenocarcinoma, which is a relatively less aggressive type of lung cancer.
2. The tumor size is 2.5 cm, which is relatively small and may not have spread to distant sites.
3. The margins are negative, indicating that the tumor has not spread to the surrounding tissue.
4. There is no evidence of vascular or lymphatic invasion, which suggests that the tumor has not spread to the bloodstream or lymphatic system.
5. All examined regional lymph nodes (five in total) and the fat pad biopsy were negative for malignancy, indicating that the tumor has not spread to the lymph nodes.
6. The tumor shows invasion towards the pleural surface but does not directly involve the visceral pleura, which suggests that the tumor has not spread to the pleura.

Based on these findings, I would conclude that the patient has a good prognosis and is likely to survive after 2.48 years.

Answer: {""Survival"": ""True""}"
22,"Here are the reasoning steps:

1. The pathology report indicates the presence of metastatic carcinoma in multiple lymph nodes, which suggests that the cancer has spread beyond the primary tumor site.
2. The tumor size is approximately 1.7 cm, which is relatively small, but the presence of lymphatic invasion and capsular penetration indicates that the cancer has invaded the surrounding tissue.
3. The surgical margins are negative for carcinoma, which suggests that the tumor has not spread to the surrounding tissue, but the presence of metastatic carcinoma in multiple lymph nodes indicates that the cancer has already spread to other parts of the body.
4. The findings are consistent with a pulmonary primary, excluding breast carcinoma as the source of the metastasis, which suggests that the primary tumor is located in the lung.

Based on these findings, it is likely that the patient will not survive after 2.48 years. The presence of metastatic carcinoma in multiple lymph nodes and the evidence of lymphatic invasion and capsular penetration indicate that the cancer has already spread to other parts of the body, which is a poor prognostic factor.

Answer: {""Survival"": ""False""}"
23,"Here are the reasoning steps:

1. The patient has a localized lung adenocarcinoma, meaning the tumor is confined to the lung and has not spread to other parts of the body.
2. The tumor is moderately differentiated, which suggests that it is not highly aggressive.
3. The surgical margins are clear, indicating that the tumor has been completely removed.
4. There is no pleural involvement, which means the tumor has not spread to the lining of the lung.
5. The lymph nodes from various levels are negative for malignancy, indicating that the cancer has not spread to the lymph nodes.

Based on these findings, it is likely that the patient will survive for at least 2.48 years without the cancer spreading to other parts of the body.

Answer: {""Survival"": ""True""}"
24,"Here are the reasoning steps:

1. The patient has a diagnosis of adenocarcinoma (not otherwise specified) in the left upper lobe of the lung.
2. The tumor size is 6.5 x 6.5 x 5.0 cm, which is a relatively large tumor.
3. The tumor has invaded the lymph nodes (pN1), which indicates regional lymph node involvement.
4. The tumor is classified as pT2b, which indicates that it has invaded the lung tissue beyond the primary tumor site.
5. The tumor is classified as G3, which indicates that it is poorly differentiated.
6. The immunohistochemical analysis shows that the tumor cells are positive for CK7 and have a Ki-67 proliferation index of 40%, which suggests that the tumor is aggressive.

Based on these findings, it is likely that the patient will not survive for 2.48 years. The tumor is large, has invaded the lymph nodes, and is poorly differentiated, which suggests that it is likely to be aggressive and have a poor prognosis.

Answer: {""Survival"": ""False""}"
25,"Here are the reasoning steps:

1. The patient has metastatic adenocarcinoma, which means the cancer has spread beyond the primary tumor site.
2. Eight out of twelve lymph nodes from the left lung show positive results for cancer, indicating widespread metastasis.
3. The tumor is moderately to poorly differentiated, which suggests a more aggressive behavior.
4. The tumor has lymphovascular invasion, which means it has invaded the lymphatic and blood vessels, allowing it to spread further.
5. The tumor has direct extension into two intraparenchymal lymph nodes, which means it has invaded the lymph nodes directly.
6. Molecular analysis for EGFR mutations was performed, but no mutations were detected. This suggests that the patient may not be a candidate for targeted therapy.
7. A polymorphism of uncertain clinical significance was noted, which may or may not have any impact on the patient's prognosis.

Based on these findings, it is likely that the patient will not survive after 2.48 years. The widespread metastasis, aggressive behavior, and direct invasion of lymph nodes suggest a poor prognosis.

Answer: {""Survival"": ""False""}"
26,"Here are the reasoning steps:

1. The patient has a diagnosis of invasive adenocarcinoma, which is a type of lung cancer.
2. The tumor is classified as pT2a, which means it is a tumor that is 2 cm or less in size and has not invaded the visceral pleura or large vessels.
3. The tumor has also invaded one lymph node (hilar node #2), which is classified as pN1.
4. The resection margins are clear of tumor, which means that the surgeon removed the entire tumor and there is no evidence of remaining cancer cells.
5. The patient's TNM stage is pT2a, pN1, pMX, which indicates that the tumor is stage II, with a moderate level of lymph node involvement.

Based on these findings, the patient's prognosis is likely to be good, with a high chance of survival. However, the patient will still require follow-up care and monitoring to ensure that the cancer does not recur.

Answer: {""Survival"": ""True""}"
27,"Here are the reasoning steps:

1. The pathology report indicates the presence of metastatic adenocarcinoma in peribronchial lymph nodes, which suggests that the cancer has spread beyond the primary tumor site.
2. The tumor invades the visceral pleura, which is a sign of local invasion.
3. There is no evidence of vascular invasion, which is a good sign.
4. Lymphatic invasion is pending, but even if it is positive, it would not change the overall prognosis.
5. The presence of centrilobular emphysema, pulmonary hemosiderosis, and necrotizing granulomas in the lymph nodes is not directly related to the patient's survival.
6. The tumor has a size of 3.5 x 2.8 x 2.5 cm, which is relatively large.

Based on these findings, I conclude that the patient is unlikely to survive after 2.48 years. The presence of metastatic disease in lymph nodes and local invasion of the visceral pleura are strong indicators of poor prognosis.

Answer: {""Survival"": ""False""}"
28,"Here are the reasoning steps:

1. The patient has a poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor is 58 mm in size, which is relatively large.
3. The tumor has visceral pleural invasion, which means it has invaded the lining of the lung, and has also invaded the chest wall.
4. There is evidence of blood vessel invasion, which can lead to distant metastasis.
5. However, there is no lymphatic or perineural invasion, which is a good sign.
6. No lymph node metastases were found, which is also a good sign.
7. The tumor is clear of the bronchial resection margin, which means the surgeon was able to remove the tumor completely.

Considering these factors, I would conclude that the patient's prognosis is poor. The tumor is large, has invaded surrounding tissues, and has blood vessel invasion, which increases the risk of distant metastasis. However, the fact that there is no lymphatic or perineural invasion, and no lymph node metastases, suggests that the tumor may not have spread as far as it could have.

Based on this analysis, I would select answer:

{""Survival"": ""False""}"
29,"Here are the reasoning steps:

1. The pathology report indicates a diagnosis of poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor size is 3.5 x 3 cm, which is relatively small.
3. There is no evidence of venous invasion, which is a good sign.
4. All 7 hilar lymph nodes examined were negative for metastasis, indicating that the cancer has not spread to the lymph nodes.
5. The surgical margins are uninvolved, suggesting that the tumor was completely resected.

Based on these findings, the patient has a good prognosis and is likely to survive after 2.48 years.

Answer: {""Survival"": ""True""}"
30,"Here are the reasoning steps:

1. The patient has a Stage IIB lung adenocarcinoma, which is an early stage of cancer.
2. The tumor is 3.7 cm in size, which is relatively small.
3. There is no visceral pleural invasion or lymph-vascular invasion, which suggests that the cancer has not spread to other parts of the body.
4. All examined lymph nodes (11 total) are negative for cancer, indicating that the cancer has not metastasized to the lymph nodes.
5. Ancillary studies show no EGFR mutations detected, which suggests that the cancer is not driven by a specific genetic mutation.

Based on these findings, the patient has a good prognosis and is likely to survive after 2.48 years.

Answer: {""Survival"": ""True""}"
31,"Here are the reasoning steps:

1. The patient has a diagnosis of non-small cell carcinoma, specifically adenocarcinoma, poorly differentiated, which is an aggressive type of lung cancer.
2. The tumor size is 3.5 cm, which is considered large and may indicate a higher risk of recurrence and metastasis.
3. The tumor has invaded into visceral pleura and large vessels, which suggests that the cancer has spread beyond the primary tumor site.
4. Regional lymph nodes showed metastases in the ipsilateral peribronchial and hilar lymph nodes, which indicates that the cancer has spread to the lymph nodes.
5. However, multiple lymph node biopsies from various stations were negative for malignancy, which suggests that the cancer has not spread to other lymph nodes.
6. The bronchial margins were reported as free of tumor, with a distance of 5 mm from the invasive carcinoma to the closest margin, which suggests that the surgery was able to remove the primary tumor with a reasonable margin.

Based on these findings, I would conclude that the patient has a high risk of recurrence and metastasis, and the prognosis is poor. Therefore, the answer is:

{""Survival"": ""False""}"
32,"Here are the reasoning steps:

1. The patient has a poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor is 2.5 cm in size, which is relatively large.
3. There is a suggestion of visceral pleural invasion, which means the tumor has invaded the lining of the lung.
4. The surgical margins are uninvolved, which means the tumor has not spread to the surrounding tissue.
5. The right lower lobe lobectomy showed no residual malignancy, which means the tumor has been completely removed.
6. Two lymph nodes from the specimen were negative for metastatic disease, which means the tumor has not spread to the lymph nodes.
7. However, the level 12 nodes demonstrated evidence of metastasis, which means the tumor has spread to the lymph nodes in that area.

Based on these findings, I would conclude that the patient's prognosis is poor. The tumor is aggressive, has invaded the pleura, and has spread to the lymph nodes. Therefore, I would select option (B) False.

Answer: {""Survival"": ""False""}"
33,"Here are the reasoning steps:

1. The patient has a poorly differentiated adenocarcinoma, which is an aggressive type of lung cancer.
2. The tumor invades the pleura, which is a poor prognostic factor.
3. Vascular invasion is also present, which increases the risk of distant metastasis.
4. Although the surgical margins are negative for tumor, the presence of vascular invasion suggests that the tumor may have already spread beyond the primary site.
5. There is no evidence of regional lymph node involvement or distant metastasis noted in the report, but this does not necessarily mean that the tumor has not spread.
6. Given the aggressive features of the tumor, it is likely that the patient will not survive for 2.48 years.

Answer: {""Survival"": ""False""}"
34,"Here are the reasoning steps:

1. The patient has a stage T2N0MX, which means the tumor is 2.8 cm in size, has invaded the visceral pleura and angiolymphatic vessels, but has not metastasized to the lymph nodes.
2. The surgical resection margins are free of tumor, indicating that the tumor has been completely removed.
3. There is no evidence of distant metastasis (MX).
4. The tumor is moderately differentiated, which is a favorable prognostic factor.
5. The patient has chronic inflammation and submucosal scarring in the respiratory mucosa, which may be a sign of chronic lung disease, but it is not a direct indicator of survival.
6. The patient has background emphysematous changes in the lung, which may be a sign of chronic lung disease, but it is not a direct indicator of survival.

Based on these factors, I would conclude that the patient has a good prognosis and is likely to survive after 2.48 years.

Answer: {""Survival"": ""True""}"
35,"Here are the reasoning steps:

1. The pathology report indicates a diagnosis of poorly differentiated non-small cell carcinoma, which is a broad category that includes several subtypes of lung cancer.
2. The report notes that the tumor is positive for TTF-1 and negative for p63, CK5/6, CK7, and CK20, which suggests that the tumor is likely an adenocarcinoma.
3. The report also notes that all examined lymph nodes were negative for carcinoma, which suggests that the tumor has not metastasized to the lymph nodes.
4. The report mentions that further characterization of the tumor type is pending additional immunoevaluation, which suggests that the tumor type is not yet fully determined.

Based on these findings, it is likely that the patient will survive after 2.48 years. The tumor is poorly differentiated, but it has not metastasized to the lymph nodes, which is a good prognostic sign. Additionally, the tumor is likely an adenocarcinoma, which is a more indolent subtype of lung cancer compared to squamous cell carcinoma.

Answer: {""Survival"": ""True""}"
36,"Here are the reasoning steps:

1. The patient underwent a right lung pneumonectomy, which suggests that the tumor was completely removed.
2. The tumor is poorly differentiated adenocarcinoma with clear cell changes, which is an aggressive type of lung cancer.
3. However, the tumor did not invade the visceral pleura, which is a good sign.
4. The bronchial and vascular margins are also negative for tumor, indicating that the tumor was completely removed.
5. All examined lymph nodes from levels 4, 7, and 9, as well as a portion of the sixth rib, showed no evidence of tumor, suggesting that there is no metastatic spread to the lymph nodes.
6. Given that the tumor was completely removed and there is no evidence of metastatic spread, the patient has a good chance of survival.

Based on these findings, I would conclude that the patient will survive after 2.48 years. Therefore, the answer is:

{""Survival"": ""True""}"
37,"Here are the reasoning steps:

1. The pathology report indicates that the patient has a mixed acinar and bronchioloalveolar adenocarcinoma, which is a type of lung cancer.
2. The tumor is moderately to poorly differentiated, which suggests that it may be more aggressive and have a poorer prognosis.
3. The tumor has metastasized to one of two resected lymph nodes, which indicates that the cancer has spread beyond the primary tumor site.
4. The KRAS mutation analysis is positive, which suggests that the patient may have a more aggressive form of lung cancer.

Based on these factors, it is likely that the patient will not survive after 2.48 years. The presence of metastatic disease and a KRAS mutation are both poor prognostic indicators for lung cancer patients.

Answer: {""Survival"": ""False""}"
